Market Closed -
Other stock markets
|
After market 11:53:30 am | |||
3.59 EUR | +2.92% | 3.594 | +0.11% |
May. 30 | Clariane: Leima Valeurs exceeds 5% of capital & voting rights | CF |
May. 28 | Clariane: Canadian investment board falls below 5% threshold | CF |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- This company will be of major interest to investors in search of a high dividend stock.
Weaknesses
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+49.33% | 405M | B+ | ||
+23.51% | 86.96B | C+ | ||
-23.70% | 75.65B | B- | ||
+0.49% | 26.97B | C+ | ||
+5.59% | 17.89B | A- | ||
-13.19% | 16.58B | B | ||
+2.97% | 15.73B | A- | ||
+75.93% | 13.01B | C- | ||
+79.69% | 12.92B | C+ | ||
+37.55% | 12.57B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CLARI Stock
- Ratings Clariane SE